Navigation Links
Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
Date:10/26/2010

THE WOODLANDS, Texas, Oct. 26 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will release its third quarter 2010 financial results on Friday, November 5, 2010 before the financial markets open.  Lexicon management will hold a conference call to discuss its clinical development progress and financial results for the quarter at 11:00 a.m. Eastern Time that same day.

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 20791091.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the webcast will be available on the website through November 12, 2010.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
2. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
3. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
4. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
5. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
6. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
7. Lexicon to Present at BIO International Convention
8. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
9. Lexicon Announces Proposed $95 Million Common Stock Offering
10. Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... Patient ... loss of blood during surgeries, lowering the risks of neurological ... risks of SSIs. The patient warming systems can be segmented ... systems.These benefits in turn reduce the stay at hospitals thus, ...
(Date:12/8/2016)... 8, 2016 Global Interventional Radiology Market: ... global interventional radiology market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... largest share of the market in 2016 and is ... can be attributed to a large number of surgical ... hold the largest share in the patient temperature management ... such as reducing loss of blood during surgeries, lowering ...
Breaking Medicine Technology:
(Date:12/10/2016)... ... December 10, 2016 , ... The Pennsylvania ... recently joined forces with other healthcare organizations to promote diabetes education at the ... Harrisburg, featured a variety of speakers from around the Commonwealth of Pennsylvania. ...
(Date:12/9/2016)... WA (PRWEB) , ... December 09, 2016 , ... ... financial planning assistance from offices in Pasco and Richland, is initiating a charity ... overcome serious injuries resulting from a recent automobile collision. , On October ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch ... Inc. (NCADD) is recommending the film Whispering Spirits and its discussion ... of Columbia as an education tool in the war against teen drug abuse. ...
(Date:12/9/2016)... Fort Lee, NJ (PRWEB) , ... December 09, ... ... the 2016 Founders Ball at The Pierre Hotel in New York, NY, on ... 700 friends, benefactors, dignitaries and physicians attended the annual event, which raised over ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... become Quality Insights beginning January 1, 2017. The name change aligns the ... to measuring and improving health care quality. , “We are very proud of ...
Breaking Medicine News(10 mins):